跳至主要内容
临床试验/NCT00463554
NCT00463554已完成不适用

An Evaluation of the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) for the Treatment of Stress Urinary Incontinence *Trademark

Ethicon, Inc.6 个研究点 分布在 3 个国家目标入组 72 人开始时间: 2006年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ethicon, Inc.
入组人数
72
试验地点
6
主要终点
Clinical performance of TVT-SECUR*

研究概览

简要总结

The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).

详细描述

The primary variable for effectiveness is > 50% improvement on the subjective symptom Visual Analog Scale (VAS) at Visit 3/Week 5 (35 days post-surgery) to be accepted.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Must be female with objective, demonstratable signs of SUI or stress predominant mixed incontinence and requires elective, primary surgical intervention.
  • Must be at least 21 years old.
  • Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.
  • Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent

排除标准

  • Have any other coexistent pathology requiring concomitant surgery that may impact this procedure i.e. surgeries that involve the anterior vaginal wall (e.g. anterior colporrhaphy, diverticula, anterior Prolift) Any allowable concomitant surgery must be performed prior to the GYNECARE TVT SECUR System surgery.
  • Have intrinsic sphincter deficiency (ISD) [Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) < 20cm H2O or Leak Point Pressure (LPP) < 60].
  • Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.
  • Have a fixed urethra (< 30° mobility on Q-Tip Straining Test).
  • Have had prior incontinence surgery.
  • Have a post-void residual volume > 100mL.
  • Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.
  • Have lower urinary tract pathology in the form of a fistula or diverticulum.
  • Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.
  • Are on anticoagulant therapy.
  • Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.
  • Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.
  • Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.

结局指标

主要结局

Clinical performance of TVT-SECUR*

时间窗: Screening and Day 35

次要结局

  • Urodynamics(Screening, Week 5, Months 6 and 12 (post-operative optional))
  • Intra- and post-operative complications(Intraoperative, Week 5, Months 6 and 12)
  • Anesthesia(intraoperative)
  • Operative time(Intraoperative)
  • Assessment of the results of the standing cough stress test(Screening, Week 5, Months 6 and 12)
  • Physician questionnaire results(Months 2 and 12)
  • QoL measures(Screening, Week 5, Months 6 and 12)
  • Subject satisfaction.(Month 12)

研究者

发起方
Ethicon, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

TVT-SECUR A Pilot Study for the Treatment of Stress... | 临床试验